Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01904487 · ClinicalTrials.gov registry record · Phase 1
Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence
A Phase 1 study, sponsored by Rajesh Narendran.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT01904487 is a Phase 1 study that has completed, run by Rajesh Narendran. The registered enrollment target is 11 participants.
The verdict
NCT01904487, a Phase 1 study, has completed, sponsored by Rajesh Narendran.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
Background: \- This study is being done to examine the role of a chemical GABA in the brain of alcohol dependent patients. GABA is the chief inhibitory neurotransmitter in the central nervous system. It helps induce relaxation and sleep and balances the brain by inhibiting over-excitation. Several studies have reported that anxiety disorders such as panic attacks, seizure disorders, and numerous other conditions including addiction, are all related to low GABA activity. Therefore, we will examine differences in GABA levels between healthy controls and subjects with alcohol addiction. Studies such as this are important to the understanding of the role of GABA in alcohol addiction.
Interventions
- DRUG Tiagabine
- RADIATION [11C]flumazenil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04-19 |
| Est. Completion | 2013-10-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01904487
The ClinicalTrials.gov registry entry for NCT01904487 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rajesh Narendran, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiagabine is the first listed.
NCT01904487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01904487 about?
NCT01904487 is a clinical study titled "Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence". Background: \- This study is being done to examine the role of a chemical GABA in the brain of alcohol dependent patients. GABA is the chief inhibitory neurotransmitter in the central nervous system. It helps induce relaxation and sleep and balances the brain by inhibiting over-excitation. Several ...
What is the current status of trial NCT01904487?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-04-19. Estimated completion is 2013-10-01.
What interventions are being tested in trial NCT01904487?
The interventions under investigation include: Tiagabine (DRUG), [11C]flumazenil (RADIATION).
Who is sponsoring clinical trial NCT01904487?
This trial is sponsored by Rajesh Narendran, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.